According to a recent report, Grøntvedt Biotech has launched CETO3, an omega-3 and cetoleic acid product called “omega 11” cetoleic acid. The report was published in the leading international publisher, Nutrition Insight.
The product has the ability to convert the plant-based omega 3 alpha-lipoic acid (ALA) into eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in liver cells. The product is obtained from Norwegian herring and is useful for maintaining heart and skin health. CETO3 is equipped to meet the growing demands for marine omega 3 sources. It has unique sensory qualities and is 100% obtained from traceable and sustainable source. Due to its sensory qualities, CETO3 can be used for nutraceuticals in capsule and liquid formulations.
A study funded by the Norwegian Seafood Research Fund showed that cetoleic acid boosted the conversion of ALA into the omega 3 fatty acids EPA and DHA, in human liver cells. These fatty acids help improve sleep quality, chronic pain relief, and has a modifying effect on the immune response during pregnancy. The production of EPA and DHA was shown to increase by 40%. Grøntvedt Biotech is aiming to scale up CETO3 production and bring it to the global market.
Source: Jolanda van Hal. Omega 11: Grøntvedt Biotech launches CETO3 for omega 3 and cetoleic acid product. Nutrition Insight. 13 February, 2023.
https://www.nutritioninsight.com/news/omega-11-gr%C3%B8ntvedt-biotech-launches-ceto3-for-omega-3-and-cetoleic-acid-product.html#:~:text=13%20Feb%202023%20%2D%2D%2D%20Gr%C3%B8ntvedt,(DHA)%20in%20liver%20cells
